This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Astex Pharmaceuticals Announces Initiation Of AT13387 Phase 2 Study In Non-Small Cell Lung Cancer

Stocks in this article: ASTX

DUBLIN, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated an open label, randomized, controlled, multi-center, Phase 2 clinical trial, evaluating HSP90 inhibitor AT13387 in anaplastic lymphoma kinase positive (ALK +) non-small cell lung cancer patients or other potentially crizotinib-sensitive NSCLC patients who have been receiving crizotinib. The trial will evaluate AT13387 as both single agent and in combination with crizotinib in these patients.

The AT13387 study will consist of three parts. Part A is a lead-in, single arm, dose escalation segment of the trial in patients with NSCLC who have already been receiving crizotinib, to establish the Maximum Tolerated Dose (MTD) of the combination. Once the MTD is defined in Part A, and depending on the patient's response to crizotinib, Parts B and C will ensue in which patients will be randomized to continue to receive crizotinib alone, AT13387 alone, or the combination of AT13387 with crizotinib.

"This is the most comprehensive study designed to date to investigate the efficacy and safety of an HSP90 inhibitor in patients who are sensitive to an ALK+ inhibitor," said Mohammad Azab, MD, chief medical officer. "The study will permit us to identify a clear role of HSP90 inhibition by AT13387 both as a single agent and in combination with an ALK+ inhibitor in the treatment of NSCLC."

About the Study

The primary objective of Part A of this trial is to determine the safety and tolerability of combination therapy with AT13387 and crizotinib and to determine the MTD for Parts B and C. The primary objective in Part B will be to compare the efficacy by response rate between continued administration of single agent crizotinib versus the combination of AT13387 plus crizotinib in patients who were treated for at least 8 weeks with crizotinib and have not yet progressed. Lastly, the primary objective of Part C will be to test the efficacy by response rate of single agent AT13387 and the combination of AT13387 and crizotinib in patients who progressed on treatment with crizotinib.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs